Two-year observational study of deferiprone in superficial siderosis.

CONCLUSION: This is the first long-term prospective study of superficial siderosis on the iron chelator, deferiprone. MRI quantification of hemosiderin appears to demonstrate a measurable reduction in half of patients and this correlated with a stabilized or improving disease course. A future placebo-controlled trial is necessary to determine whether deferiprone is an effective therapy for superficial siderosis.
PMID: 29285884 [PubMed - as supplied by publisher]

Source: CNS Neuroscience and Therapeutics - December 28, 2017 Category: Neuroscience Authors: Kessler RA, Li X, Schwartz K, Huang H, Mealy MA, Levy M Tags: CNS Neurosci Ther Source Type: research